MetaCap

Rhythm Pharmaceuticals Financial Ratios

NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

90.78+1.14 (+1.27%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Rhythm Pharmaceuticals ratio analysis

Rhythm Pharmaceuticals earned a net margin of -103.6% in FY 2025, up from -200.3% a year earlier. Gross margin was 89.7% compared with a median of 88.9% over the prior 4 years. Return on equity reached -141.3%, meaning Rhythm Pharmaceuticals generated -1.41 dollars of profit for every dollar of shareholders' equity.

Debt-to-equity stood at 0.78 versus 5.05 the year before, and the current ratio was 4.41. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.

Summary generated from market data by MetaCap's automated system. Methodology

Rhythm Pharmaceuticals financial ratios (annual)

Rhythm Pharmaceuticals annual financial ratios
RatioFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Price / sales35.9627.9534.2464.21156.95—————
Price / book49.07167.3615.625.741.747.882.883.352.66—
Gross margin89.7%89.7%88.0%91.0%81.0%—————
Operating margin-101.2%-204.0%-238.1%-757.9%-5,391.9%—————
Net margin-103.6%-200.3%-238.5%-766.2%-2,207.1%—————
Free cash flow margin-61.5%-87.5%-175.9%-734.9%-4,642.9%—————
Return on equity (ROE)-141.3%-1,199.3%-108.8%-68.5%-24.5%-80.5%-50.1%-30.1%-23.3%—
Return on assets (ROA)-40.9%-66.4%-55.5%-47.4%-21.1%-71.6%-45.6%-28.5%-22.2%-209.7%
Debt / equity0.785.050.63———————
Current ratio4.413.245.588.907.1010.1012.3819.0522.422.36
Revenue growth45.8%68.1%227.6%649.5%——————

Related